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 ABSTRACT 
One of the main limitations of pharmacological fMRI is its inability to provide a molecular 
insight into the main effect of compounds, leaving an open question about the relationship 
between drug effects and haemodynamic response. The aim of this study is to investigate the 
acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on functional connectivity 
(FC) using a novel multimodal method (Receptor-Enriched Analysis of functional Connectivity 
by Targets - REACT). This approach enriches the resting state (rs-)fMRI analysis with the 
molecular information about the distribution density of serotonin receptors in the brain, given 
the serotonergic action of MDMA.  
Twenty healthy subjects participated in this double-blind, placebo-controlled, crossover study. 
A high-resolution in vivo atlas of four serotonin receptors (5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4) 
and its transporter (5-HTT) was used as a template in a two-step multivariate regression 
analysis to estimate the spatial maps reflecting the whole-brain connectivity behaviour related 
to each target under placebo and MDMA.  
Results showed that the networks exhibiting significant changes after MDMA administration 
are the ones informed by the 5-HTT and 5-HT1A distribution density maps, which are the main 
targets of this compound. Changes in the 5-HT1A-enriched functional maps were also 
associated with the pharmacokinetic levels of MDMA and MDMA-induced FC changes in the 
5-HT2A-enriched maps correlated with the spiritual experience subscale of the Altered States 
of Consciousness Questionnaire. 
By enriching the rs-fMRI analysis with molecular data of voxel-wise distribution of the 
serotonin receptors across the brain, we showed that MDMA effects on FC can be understood 
through the distribution of its main targets. This result supports the ability of this method to 
characterise the specificity of the functional response of the brain to MDMA binding to 
serotonergic receptors, paving the way to the definition of a new fingerprint in the 
characterization of new compounds and potentially to a further understanding to the response 
to treatment. 
 
Highlights 
• MDMA connectivity effects understood through the distribution of 5-HT1A and 5-HTT 
• Direct link between PK levels of MDMA and 5-HT1A-enriched functional connectivity 
maps  
• Ability to link receptor targets to functional mechanisms underlying behaviour 
• Mapping pharmacodynamic effects onto the drug’s molecular targets 
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1. INTRODUCTION 
3,4-methylenedioxymethamphetamine (MDMA) increases levels of serotonin, dopamine and 
noradrenaline in the brain (Liechti and Vollenweider, 2001). This drug has a history of 
recreational use because of its positive effects on mood and social interaction, which include 
feelings of empathy and warmth for others, sociability and a sense of being at peace with the 
world, as well as euphoria (Rodgers et al., 2006; Sumnall et al., 2006). It can also produce mild 
visual hallucinatory phenomena, which have been linked to the 5-HT2A receptor, the same 
receptor targeted by the classic psychedelics (Gouzoulis-Mayfrank et al., 1996; Harris et al., 
2002; Liechti and Vollenweider, 2001). While currently classed in the list of Schedule I drugs, 
indicating no potential medicinal benefits, preliminary evidence of a potential clinical use of 
MDMA for mental illness (Amoroso and Workman, 2016; Mithoefer et al., 2013) has recently 
re-ignited interest in its pharmacology, behavioural effects and mechanisms of action. 
The serotonergic pharmacology of MDMA is primarily characterised by the inhibition of 5-HT 
reuptake (Iravani et al., 2000) and the stimulation of 5-HT release in the extracellular space via 
the serotonin transporter (5-HTT) (Bradbury et al., 2014; Gudelsky and Nash, 1996; Nichols, 
1986). Other studies have also shown a weaker affinity of MDMA to 5-HT1A and 5-HT2A receptor 
sites (Green et al., 2003; Ray, 2010) as well as non-serotonergic effects (Hasler et al., 2009). 
Some behavioural effects of MDMA such as feelings of empathy, sociability, and interpersonal 
closeness (Rodgers et al., 2006; Sumnall et al., 2006) are thought to be induced in part by an 
increase in the levels of the peptide oxytocin (Dumont et al., 2009; Hysek et al., 2012) with 5-
HT1A receptor playing an important role in this mechanism (Mottolese et al., 2014; Thompson 
et al., 2007).  
 While MDMA pharmacology has been extensively investigated in terms of its primary targets 
and affinities, its effect on brain function is less well understood. The investigation of MDMA-
induced effects on brain function using resting state fMRI (rs-fMRI) has been focused on 
specific regions related to social and affective processing, namely the insula, ventromedial 
prefrontal cortex, hippocampus and amygdala (Carhart-Harris et al., 2015; Walpola et al., 
2017). These studies revealed changes in functional connectivity for circuitry implicated in 
anxiety and stress-related disorders such as the medial prefrontal cortex, medial temporal 
regions, amygdala and hippocampus (Carhart-Harris et al., 2015) and a reduction in insula 
connectivity which correlated with the acute subjective experiences of altered bodily 
sensations and baseline trait anxiety (Walpola et al., 2017). An independent component 
analysis (ICA) was performed on the same dataset (Carhart-Harris et al., 2015; Walpola et al., 
2017) to evaluate the effects of MDMA on functional connectivity (FC) between the resting 
state networks (RSNs). This analysis revealed an increased FC between the executive control 
network the anterior default mode network (Roseman et al., 2014).  
One of the main limitations of pharmacological fMRI is its inability to provide a molecular 
insight into the main effect of compounds. In fact, this imaging technique relies on the strong 
assumption that haemodynamic changes can be considered a proxy of altered 
neurotransmission due to pharmacological agonism or antagonism actions (Attwell and 
Iadecola, 2002), but the fMRI signal has no intrinsic selectivity to any particular receptor sites. 
Therefore, the degree to which the fMRI response indexes the action at drug target sites, which 
could be useful in parsing mechanistic underpinnings, is still an open question.  
Here we propose Receptor-Enriched Analysis of functional Connectivity by Targets (REACT), a 
method that utilises the molecular information about target distribution provided by Positron 
Emission Tomography (PET) to enrich the pharmacological rs-fMRI analysis. In particular, we 
tested the degree to which the haemodynamic response to MDMA mirrors the 5-HT receptor 
density profiles, given its known mixed profile of serotonergic action. We used a publicly 
available atlas (Beliveau et al., 2017), which provides the 5-HT receptor density profiles for 5-
HT1A, 5-HT1B, 5-HT2A and 5-HT4 receptors and the 5-HTT transporter, as target-site distribution 
maps in a two-step multivariate regression analysis and estimated the spatial maps reflecting 
the whole-brain connectivity behaviour related to each target, in order to link the knowledge 
about their distribution with the main effect of MDMA on functional connectivity. All the 
available PET maps were included in the model as we wanted to test the ability of this method 
to characterise the specificity of the functional response of the brain to MDMA binding to 
serotonergic receptors. Given MDMA affinity profiles and proposed mediators of MDMA 
effects at the 5-HTT transporter, the 5-HT1A and 5-HT2A receptor targets (Bradbury et al., 2014; 
Green et al., 2003; Gudelsky and Nash, 1996; Liechti and Vollenweider, 2001; Nichols, 1986; 
Ray, 2010; Thompson et al., 2007) we hypothesised that functional connectivity informed by 
these three target maps will be sensitive to MDMA administration.  
In addition to the derivation of the spatial maps according to each receptor density 
distribution, it is possible that the interaction between the targets has a significant influence 
on FC. For example, both the 5-HTT and the 5-HT1A are important for serotoninergic regulation 
and their in vivo receptor densities are related both within the brain stem (e.g. raphe nucleus) 
and at the more distal sites (Bose et al., 2011). Therefore, we set out to explore whether or 
not overlapping expressions of serotonergic targets are also associated with the main effect of 
MDMA on FC. 
Finally, we investigated whether subjective effects and pharmacokinetic (PK) measures, such 
as MDMA plasma levels and MDMA-induced increases in the plasma levels of oxytocin, are 
linked with the pharmacodynamic effects of MDMA in the brain, exploring possible 
relationships with the 5-HT receptor distribution. 
2. METHODS 
2.1 Participants 
Twenty-one male participants were recruited from the community and passed screening, 
which included prior experience of MDMA/ecstasy. Twenty of these participants completed 
the study (mean age 24.8 y, SD = 3.7, range = 21 – 37), while one participant withdrew from it 
after his first visit. This was unrelated to his participation and unblinding revealed that he 
received placebo on that visit. Participants were excluded if they had personal history of 
psychiatric illness (assessed with the Mini-International Neuropsychiatric Interview, Sheehan 
et al., 1998); first-order relative with a history of psychotic illness; evidence of cardiac (assessed 
with ECG), hepatic, renal, gastrointestinal (assessed with standard blood screening) or 
neurological disorders; excessive use of caffeine (> six cups of coffee per day) and alcohol (> 
28 units per week); current use of medication; failure of drugs of abuse test at screening or on 
either study day (drugs tested for: amphetamine, barbiturates, benzodiazepines, cocaine, THC, 
methadone, methamphetamine, opiate, MDMA, tricyclic antidepressants). Participants were 
only included in this study if they had at least one previous experience with MDMA. They were 
also required to have not used MDMA in the three months leading up to their involvement in 
the study.  
All participants gave written informed consent to take part in the study and were financially 
compensated for their time. The study received ethical approval from King’s College London’s 
Psychiatry, Nursing and Midwifery Research Ethics Committee (PNM/14/15-32). All 
experiments were performed in accordance with relevant guidelines and regulations.  
2.2 Study design and behavioural analyses 
Data was collected using a within-subjects, double-blind randomized, placebo-controlled, 
crossover design. Following a successful screening, participants attended two experimental 
study days at least one week apart (mean 9.3 days, SD 5.7, range 7–31). For a full description 
of the experimental day, see (Gabay et al., 2018a). 
Subjective effects were assessed using the 11-dimension Altered States of Consciousness 
Questionnaire (ASC), the gold standard when investigating compounds with psychedelic-like 
properties (Studerus et al., 2011).  
MDMA plasma levels were measured 45 minutes post-dose and 165 minutes post-dose. 
Oxytocin plasma levels were measured at these same timepoints, as well as 15-minutes pre-
dose to obtain a baseline measure. 
2.3 Image acquisition 
MR imaging was performed on a MR750 3 T General Electric MR scanner using a 32-channel 
head coil. A 3D T1-weighted anatomical scan was obtained for each participant in one session 
using an MPRAGE acquisition (TR = 7.312 ms, TE = 3.02 ms, flip angle = 11⁰, slice thickness = 
1.2 mm, 196 sagittal slices, FOV = 270mm). Functional MRI data were obtained during rest in 
both sessions using a multi-echo EPI sequence (TR = 2500 ms, TEs = 12, 28, 44 ms, resolution 
= 3.75×3.75×4.2 mm, slice thickness = 3 mm, 27 axial slices aligned to the AC-PC line, 192 
volumes, flip angle = 80°, field of view: 240mm). Participants were instructed to remain awake 
with their eyes open and fixate on a cross for the duration of the resting state scan. The resting 
state scan commenced approximately 90 minutes post-dose (mean 99.5 minutes, SD 5.5 
minutes). 
2.4 Image pre-processing  
The rs-fMRI dataset was pre-processed using AFNI (Cox, 1996) and FMRIB Software Library 
(FSL). Pre-processing steps included volume re-alignment, time-series de-spiking and slice time 
correction. After the pre-processing, functional data were optimally combined (OC) by taking 
a weighted summation of the three echoes using an exponential T2* weighting approach 
(Posse et al., 1999). The OC data were then de-noised with the Multi-Echo ICA (ME-ICA) 
approach implemented by the tool meica.py (Version v2.5 beta9) (Kundu et al., 2013; Kundu 
et al., 2014) to remove motion artefacts and other non-BOLD sources of noise. This de-noising 
method has proved its effectiveness in reducing the non-BOLD sources of noise compared to 
the standard regression approaches, and increasing the temporal SNR (Dipasquale et al., 2017; 
Kundu et al., 2013). Briefly, multi-echo principal component analysis was first used to reduce 
the data dimensionality in the OC dataset. Spatial ICA was then applied, and the independent 
component time-series were fit to the pre-processed time-series from each of the three 
echoes to generate ICA weights for each echo. These weights were then fitted to the linear TE-
dependence and TE-independence models to generate F-statistics and component-level κ and 
ρ values, which respectively indicate BOLD and non-BOLD weightings. The κ and ρ metrics were 
then used to identify non-BOLD-like components to be regressed out of the OC dataset as noise 
regressors. Further technical details on ME-ICA can be found in (Kundu et al., 2015).  
Data were then spatially smoothed with a with an 8-mm FWHM Gaussian kernel. WM and CSF 
masks were obtained from the segmentation of the subjects’ structural images and eroded in 
order to minimize the contribution of grey matter partial volume effects. After co-registering 
them to each individual’s fMRI space, they were used to extract the mean WM and CSF signals 
from each participant’s pre-processed dataset. Those signals were then regressed out and a 
high-pass temporal filter with a cut-off frequency of 0.005 Hz was applied. 
A study-specific template representing the average T1-weighted anatomical image across 
subjects was built using the Advanced Normalization Tools (ANTs) (Avants et al., 2011). Each 
participant’s dataset was co-registered to its corresponding structural scan, then normalized 
to the study-specific template before warping to standard MNI152 space. Images were finally 
resampled at 1 mm3 and 2 mm3 resolution. 
 
2.5 Receptor-enriched analysis of functional connectivity  
The high-resolution in vivo atlas (Beliveau et al., 2017) of four serotonin receptors (i.e. 5-HT1A, 
5-HT1B, 5-HT2A, and 5-HT4) and the 5-HTT transporter was used to enrich the rs-fMRI analysis 
with the density distribution of these proteins in the healthy brain (Figure 1). This atlas, which 
is freely available (https://xtra.nru.dk/FS5ht-atlas/), was created from molecular and structural 
high-resolution neuroimaging data consisting of PET and MRI scans acquired in 210 healthy 
individuals. For further details on the atlas, please refer to (Beliveau et al., 2017).  
 Figure 1: High-resolution in vivo atlas of five serotonin targets from (Beliveau et al., 2017). From left to 
right: 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4 receptors; 5-HTT transporter. 
All available serotonin target maps entered into the first step of a two-step multivariate 
regression analysis (Filippini et al., 2009; Nickerson et al., 2017; Smith et al., 2014) 
implemented in FSL (fsl_glm command). Here, the PET maps were used as a set of spatial 
regressors to estimate the FC in terms of fitting the BOLD fluctuations across voxels with 
respect to the dominant fluctuation within these maps (Griffanti et al., 2015). As the spatial 
regressors and the input data need to have the same resolution, in this step the rs-fMRI images 
sampled at 1x1x1 mm3 were used to avoid any smoothing of the receptor maps. Both rs-fMRI 
data and the design matrix were demeaned (--demean option), as required when a multiple 
regression is performed in order to obtain a good fit. Of note, this is a standard option 
implemented in the dual regression approach. The rs-fMRI volumes were masked using a 
binarized atlas derived from the PET data to restrict the analysis to the voxels for which the 
receptor density information was available in the PET maps. Of note, the cerebellum was 
excluded from this mask as the quantification of the PET data was done using cerebellar grey 
matter as reference region in the kinetic model for all the radioligands (Beliveau et al., 2017). 
The subject-specific time series estimated in this first step were then used as temporal 
regressors in a second multivariate regression analysis (second step) to estimate the subject-
specific spatial maps of the BOLD response after MDMA and placebo. At this stage, we used 
the rs-fMRI images sampled at 2x2x2 mm3 and the analysis was conducted on the whole grey 
matter volume. Again, both data and the design matrix were demeaned (--demean option); 
the design matrix columns were also normalised to unit standard deviation (--des_norm 
option), as usually performed in the second stage of the dual regression (Filippini et al., 2009). 
The general framework of this analysis is reported in Figure 2. More technical details on the 
dual regression approach can be found in (Nickerson et al., 2017). 
 Figure 2: General framework of the analysis. 
 
2.6 Interaction analysis 
An additional exploratory analysis was performed to look for interactions related to co-
localisation of serotonergic targets. For this analysis we computed the product of different 
maps and tested their non-linear combination. We focused on the targets to which MDMA has 
higher affinity, i.e. 5-HT1A, 5-HT2A and 5-HTT, and performed the two-step multivariate 
regression analysis including in the spatial GLM (first step) these three maps and their products 
(i.e., 5-HT1A * 5-HT2A, 5-HT1A * 5-HTT, 5-HT2A * 5-HTT and 5-HT1A * 5-HT2A * 5-HTT). Again, the 
temporal GLM (second step) included in the design matrix all the time series estimated in the 
first step and returned one subject-specific spatial map for every PET map and condition that 
entered in the model. 
2.7 Resting State Network Analysis 
Thirteen major RSNs were extracted from an independent rs-fMRI dataset of 43 healthy 
subjects (Wolke et al., 2019) collected on the same scanner (15 males, mean age 21.83 y, SD = 
2.05, range = 18 – 25) using the group ICA implemented with MELODIC (Beckmann and Smith, 
2004) with a model order of 20 (see supplementary figure 2). The acquisition parameters and 
pre-processing pipeline correspond to those described for the dataset under exam. The 
components classified as RSNs were then used as a template in the dual regression (Nickerson 
et al., 2017) to recover the subject-specific time series and spatial maps for both conditions. 
 
2.8 Statistical analysis 
The subject-specific target-enriched spatial maps of the two conditions, both in the main and 
in the interaction analyses, and in the RSN analysis were compared using permutation tests.  
Linear relationships were tested between the FC maps (MDMA minus Placebo) and subjective 
effects (MDMA minus Placebo), MDMA plasma levels 45 and 165 minutes after the dose 
administration (PK45 and PK165) and the MDMA and placebo difference of oxytocin peripheral 
levels 45 and 165 minutes from the administration (DOXT45 and DOXT165). 
All these tests were performed with Randomise (Winkler et al., 2014), using 5000 permutations 
per test and contrast. 
Finally, we extracted the mean FC value (MDMA minus Placebo) in the regions resulted to be 
significantly associated with the subjective effects, MDMA or oxytocin peripheral levels and 
calculated the Pearson correlation coefficients (with bootstrapping, 1000 samples) with these 
measures using SPSS.  
 
3. RESULTS 
MDMA-induced changes in subjective effects, as measured by the ASC, and plasma oxytocin 
levels can be found in Gabay et al. (2018b) (respectively in Figure 2 and Table 2 of the just 
mentioned paper). Briefly, MDMA increased scores in 10 of the 11 dimensions of the ASC 
compared to placebo (spiritual experience, blissful state, insightfulness, disembodiment, 
impaired cognition, anxiety, complex imagery, audio/visual synaesthesia, meaning, and 
experience of unity; all Bonferroni-corrected p < 0.05). Increased oxytocin levels were seen 
following MDMA treatment at both timepoints (Bonferroni-corrected p = 0.054, 45 minutes 
post-dose; Bonferroni-corrected p < 0.001, 165 minutes post-dose). On the active treatment 
day, mean MDMA plasma levels were 91.7µg/L (SD 60.2) and 188.2µg/L (SD 32.8) at 45 minutes 
and 165 minutes post-dose, respectively. 
 
3.1 Main analysis 
The two-step multivariate analysis returned one subject-specific map for each 5-HT target and 
drug condition. These target-enriched maps averaged across participants are reported in 
Figure 3. 
 Figure 3: Maps of the five serotonin targets and their respective PET-derived fMRI maps. Top row: 
density maps of the 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4 receptors and 5-HTT transporter; bottom: fMRI 
maps averaged across subjects for the placebo and MDMA conditions. 
We found significant FC decreases (pFWE < 0.05, corrected for multiple comparisons at the 
cluster level using the threshold-free cluster enhancement (TFCE) option, Bonferroni-
corrected for multiple comparisons across maps and contrasts) induced by MDMA in the maps 
enriched by the 5-HT1A receptor and the 5-HTT transporter distributions (Figure 4). Specifically, 
the effect of MDMA on FC in the 5-HT1A-enriched maps involves different cortical areas 
including the precentral and postcentral gyri, left frontal pole, left insular cortex, left inferior 
frontal gyrus, left middle temporal gyrus, left supramarginal gyrus, left opercular cortex, left 
Heschl's gyrus, left planum temporale, right superior frontal gyrus, right superior parietal 
lobule and right supplementary motor cortex. The 5-HTT-enriched maps revealed an MDMA 
effect that was localised in the anterior and posterior cingulate gyrus, precuneus, cuneal 
cortex, precentral gyrus, intracalcarine and supracalcarine cortex, lingual gyrus and lateral 
occipital cortex. Of note, no changes in the FC maps enriched by the other targets (i.e., 5-HT1B, 
5-HT2A and 5-HT4) were found. 
 Figure 4: Functional connectivity (FC) changes after MDMA in the 5-HT1A and 5-HTT-enriched maps. 
Top row: the MDMA-induced decrease in the 5-HT1A-enriched maps is localised in the precentral and 
postcentral gyri, left frontal pole, left insular cortex, left inferior frontal gyrus, left middle temporal 
gyrus, left supramarginal gyrus, left opercular cortex, left Heschl's gyrus, left planum temporale, right 
superior frontal gyrus, right superior parietal lobule and right supplementary motor cortex. Bottom 
row: the MDMA effect reported in the 5-HTT-enriched maps is localised in the anterior and posterior 
cingulate gyrus, precuneous, cuneal cortex, precentral gyrus, intracalcarine and supracalcarine cortex, 
lingual gyrus and lateral occipital cortex. Images are shown in radiological orientation. 
We also conducted a RSN analysis of MDMA uninformed by the 5-HT targets, the results of 
which are included in the supplementary materials, where we also include the results of the 
interaction analysis where the target-enriched maps and their products are included as 
regressors. Briefly, significant FC changes after MDMA compared to placebo were found in the 
primary visual, sensorimotor, medial temporal, salience and ventral stream networks. 
However, nothing survived Bonferroni correction for multiple comparisons across all the RSNs 
and contrasts. As regards the interaction analysis, we found a significant FC decrease induced 
by MDMA in the connectivity maps derived by the 5-HT1A receptor, the 5-HTT transporter and 
the HT1A – 5-HT2A interaction, and an increase in the 5-HT1A-enriched maps (pFWE < 0.05, TFCE 
corrected for multiple comparisons at the cluster level, Bonferroni corrected for multiple 
comparisons across maps and contrasts). 
3.2 Correlation with behavioural measures, MDMA and oxytocin plasma levels 
Linear relationships were tested between the FC maps derived with the REACT and subjective 
effects, MDMA and oxytocin plasma levels. 
MDMA-induced FC change in the 5-HT2A-enriched maps correlated with the spiritual 
experience subscale (r = - 0.782, p < 0.0001, 95% CI = -0.909 to -0.572; Figure 5A) in the left 
lingual gyrus and occipital and temporo-occipital fusiform gyrus, such that those with the 
greatest increases in spiritual experience had the greatest reductions in connectivity for the 5-
HT2A target-enriched maps. 
No linear relationships were found between FC maps and the oxytocin plasma levels, while 
MDMA-induced FC increases in some regions of the 5-HT1A-enriched maps were significantly 
correlated with increased plasma levels 45 minutes after MDMA administration (r = 0.9, p < 
0.0001, 95% CI = 0.71 to 0.965; Figure 5B). The correlation between FC and PK45 levels was 
localised in the right supramarginal gyrus, lateral occipital cortex and cuneal cortex. 
 
Figure 5: Correlations between behavioural measures/MDMA plasma levels and functional 
connectivity. Panel A: an MDMA-induced FC decrease in the 5-HT2A-enriched maps localised in the left 
lingual gyrus and occipital and temporo-occipital fusiform gyrus is significantly correlated with the 
spiritual experience subscale. Panel B: MDMA-induced FC increases in the right supramarginal gyrus, 
lateral occipital cortex and cuneal cortex of the 5-HT1A-enriched maps were significantly correlated 
with increased MDMA plasma levels collected 45 minutes after the dose administration. Images are 
shown in radiological orientation. 
 
For exploratory purposes, the same analysis was performed in the maps obtained in the 
interaction and RSN analyses. The results from the interaction analysis support those reported 
above, i.e. a correlation of the FC decrease after MDMA in the 5-HT2A-enriched maps with the 
spiritual experience subscale. Significant correlations were also found between MDMA-
induced FC decreases in some regions of the 5-HT1A, HT1A – 5-HTT and HT1A – 5-HT2A – 5-HTT 
maps and increased oxytocin plasma levels 165 minutes after MDMA administration. These 
results are detailed in the supplementary materials. 
As regards the RSNs, no significant correlations with the behavioural measures, MDMA and 
oxytocin plasma levels were found. 
 
4. DISCUSSION 
To date, the lack of a method to combine the knowledge about the neurochemical mechanisms 
that occur in the molecular substrate of the brain with the whole brain haemodynamic 
response measured with fMRI has limited the investigation of the link between 
pharmacokinetic and pharmacodynamic processes. In this study we proposed a novel, multi-
modal method to bridge this gap and explore the brain functional alterations induced by 
MDMA. The novelty of this approach relies on the fact that the density profiles of four 
serotonin receptors (i.e. 5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4) and its transporter (5-HTT) were 
used to inform the resting state fMRI analysis in terms of the molecular distribution of 
serotonin in the brain in order to better characterise its functional response to MDMA, given 
its known serotonergic action. This method overcomes the limitations of the traditional data-
driven and seed-based techniques used to explore resting state fMRI data in pharmacological 
challenge studies (Carhart-Harris et al., 2015; Roseman et al., 2014; Walpola et al., 2017). In 
fact, the ICA is generally used to extract common spatial patterns from heterogeneous data 
sets in order to investigate their intra- and inter-network connectivity, but the interpretation 
of the results can be challenging in the pharmacological context due to the complex structure 
of the functional networks and their interactions. By contrast, our approach defines a set of 
networks based on the a priori information about the distribution of specific targets to 
characterise the brain after a drug challenge, thus exploring the effects of pharmacological 
manipulation of brain networks from a molecular perspective. REACT shares with the seed-
based approach the fact of being an a priori method. However, conventional seed-based 
methods analyses are typically limited to specific brain regions, the choice of which is 
qualitatively informed by the literature. Here instead, we guide our analysis with quantitative 
molecular data of voxel-wise distribution of the receptors across the brain. Moreover, with 
REACT we simultaneously include different targets in the model, taking into account the effects 
of all of them in the responses of interest. 
In line with our hypothesis, we found that the networks showing significant changes after 
MDMA administration were the ones informed by the 5-HT1A and 5-HTT PET maps, which are 
the main targets of this compound. Specifically, the spatial maps enriched by the 5-HT1A 
distribution information showed a decreased functional connectivity in several cortical areas, 
including the left and right precentral and postcentral gyri, the left frontal pole, insula, 
temporal and supramarginal gyri, inferior frontal gyrus, middle temporal gyrus, supramarginal 
gyrus, opercular cortex, Heschl's gyrus, and the right superior frontal gyrus, superior parietal 
lobule and supplementary motor cortex. The 5-HTT-related maps also showed connectivity 
changes localised in the anterior and posterior cingulate cortex, precuneus, intracalcarine and 
supracalcarine cortex, lingual gyrus and precentral gyrus. These findings partly overlap with 
those reported in other Arterial Spin Labelling (ASL) and fMRI studies of MDMA in healthy 
volunteers, i.e. an involvement of the visual cortex, supplementary motor areas, and posterior 
cingulate cortex (Carhart-Harris et al., 2015). Specifically, Carhart-Harris and colleagues (2015) 
suggested that the functional changes in these areas are related to a local stimulation of 5-
HT1B receptors, high localised in the subcalcarine region of the visual cortex (Varnas et al., 
2011), due to an MDMA-induced release of serotonin. Here we were able to show that the 
MDMA effects on brain connectivity actually co-vary with the known distribution of the 5-HT1A 
and 5-HTT targets. In addition, our target-enriched method was able to replicate previous 
findings but also extend MDMA effects on FC to other areas. 
It is noteworthy that unlike the maps obtained with the traditional ICA analysis, the target-
enriched FC maps are related to the plasma levels of MDMA: the higher the level of MDMA 45 
minutes after drug administration, the higher the FC increase under MDMA in the right 
supramarginal gyrus, lateral occipital cortex and cuneal cortex. This suggests that these 
posterior cortical interactions with the areas of high 5-HT1A directly capture the functional 
impact of drug exposure, which does not simply map onto the areas where the drug will bind 
directly. 
Although the map enriched with the 5-HT2A distribution did not show a main effect, it showed 
a significant correlation with the spiritual experience subscale. Very few studies have examined 
brain systems involved in spiritual experiences, but there is converging evidence for a role of 
the inferior parietal lobule, possibly related to an altered sense of self in relation to the 
environment (Miller et al., 2018). This is an area of particularly high density of 5-HT2A receptors 
and the integration of activity of this and other areas of high 5-HT2A density was with the left 
lingual gyrus, occipital and temporo-occipital fusiform gyrus, which are regions usually 
associated with the generation of mental imagery (Cooney et al., 2010). This result is 
remarkable as it highlights the role of the 5-HT2A receptor, the principle target for 
hallucinogenic drugs, in one of the psychedelic components of the drug inducing subjective 
effects (Halberstadt, 2015). Moreover, it corroborates the hypothesis that the serotonin 2A 
receptor has a key role in the genesis of spiritual experiences (Carhart-Harris et al., 2014), and 
provides a methodology to link specific receptor targets to the neural mechanisms underlying 
subjective and behavioural outcomes. 
The maps of connectivity enriched by each target may also have predictive value in other 
functions modulated by acute MDMA challenges such as response inhibition (Schmidt et al., 
2017), where MDMA modulates activity in the right middle/inferior frontal gyrus and the 
superior parietal lobule. These areas overlap with the regions of connectivity enriched by the 
5-HT1A receptor and thus it is tempting to link the effects on response inhibition processing 
with 5-HT1A receptor mediated effects, although a specific test of such a hypothesis will be 
required by including a wider battery of tests or through blockade of receptor subtypes.  
We also explored whether or not overlapping expression of serotonergic targets had an effect 
on FC changes induced by MDMA using interaction terms in the general linear model. The 
results were largely similar to the analysis of main analysis for 5-HTT. However, there were 
some differences for the 5-HT1A-enriched maps. Taking into account the regional overlap of 
serotonin receptors, we detected an increased connectivity in the anterior cingulate gyrus, 
paracingulate gyrus, frontal pole, middle and superior frontal gyrus, all areas of particularly 
high density for the 5-HT2A receptor relative to other subtypes. Notably, this analysis revealed 
changes for the 5-HT1A-5-HT2A interaction but not for the 5-HT1A-SERT and 5-HT2A-SERT 
interactions. We note that the 5-HT1A effects are generally inhibitory, stimulating the Gi/o 
cascade, whereas the 5-HT2A stimulate the Gaq and Gby cascades which are considered 
excitatory (Gonzalez-Maeso et al., 2007; Polter and Li, 2010). Despite these differential effects 
at the synaptic level, the interpretation of the interaction at the whole brain level is not 
straightforward. First, no thresholds were applied to the maps, so all regions were included 
even if the receptor density was very low. However, thresholded overlap maps require 
knowledge of where to set the thresholds for each receptor target. Second, the PET data only 
speak to regional co-localisation (i.e. voxel-wise) rather than cellular co-localisation. Third, the 
interaction effect may be more complex and involve other receptors, including non-
serotonergic receptors. In fact, MDMA also increases extracellular levels of dopamine and 
noradrenaline, even if the clearest determinants of its effects are largely serotonergically-
mediated. Nonetheless, the aim of the present study was to determine the utility of the PET 
receptor maps for the serotonergic system in guiding the connectivity analysis of MDMA effect. 
Future investigations should take into account the precise nature of interactions between the 
receptor targets, which are currently not known. 
The results of the interaction analysis also showed a correlation of FC measures with oxytocin 
peripheral levels measured 165 minutes after the dose administration, confirming that there 
is a correlation between this neuropeptide and the functional response related to the 5-HT1A 
receptor (Thompson et al., 2007). This correlation was localised in the brain stem, 
hippocampus and in the parahippocampal gyrus. A correlation between OXT165 and MDMA-
induced FC decrease was also found in the maps representing the interaction between 5-HT1A 
– 5-HTT in the left frontal operculum cortex and among 5-HT1A – 5-HT2A – 5-HTT in the 
brainstem, right putamen and hippocampus. This is line with 5-HT and oxytocin together 
representing a functional interface for the regulation of emotion and behavior, with 
connectivity in brain stem and subcortical regions representing the functional effects of this 
interaction and supporting PET studies of interactions at the molecular level (Mottolese et al., 
2014). The correlation with oxytocin at the sample time of 165 minutes is particularly relevant 
as it is in line with the timing of oxytocin release induced by MDMA, which has been shown to 
have a peak within the interval 60 - 240 minutes (Kirkpatrick et al., 2014). For the subjective 
effects, the correlation between the MDMA-induced FC decrease in the 5-HT2A-related maps 
and the spiritual experience subscale found in the main effects analysis was also found in the 
interaction analysis, potentially indicating the selectivity of this relationship.  
With REACT, we provide a new method for exploring the changes in connectivity after 
accounting for the known binding profile of the drug. This novel approach has proven its 
effectiveness in combining the molecular knowledge from PET about the receptor distributions 
in the brain with the functional information from rs-fMRI data, providing a novel interpretation 
of the results in light of the MDMA affinity to serotonin. This is not the first multimodal study 
that integrates independent molecular atlases to functional data. The integration between 
haemodynamic markers and molecular imaging data is still a challenge. Some studies 
investigated the spatial association between the main effects of different drugs on the CBF and 
the molecular information from gene-expression, PET or autoradiography data using simple 
ROI-to-ROI correlations (Dukart et al., 2018; Selvaggi et al., 2018). While this approach has 
proven its efficacy with ASL data sets, it would be over simplistic if applied to resting state fMRI 
data, since the temporal dynamics of the BOLD signal would be overlooked. Deco and 
colleagues (2018) tackled this problem by applying an excitation/inhibition (E/I) neuro-
modulatory model combined with the 5-HT2A receptor density map from (Beliveau et al., 2017), 
fMRI and diffusion data and applied this to model the functional changes with lysergic acid 
diethylamide (LSD) in healthy participants. Similarly, we addressed this issue by combining rs-
fMRI with the underlying neuroreceptor distributions in order to clearly link the functional 
response to a specific drug (i.e., the MDMA) with the molecular substrates. However, the main 
difference in REACT compared to the approach developed by Deco and colleagues is the 
weighting of the resting state signal on the basis of the molecular distribution of multiple 
serotonin receptor targets across the brain, without taking into account any a priori neuro-
modulatory model of the E/I balance. 
Further specification from intra-regional variation across subjects is not possible using the 
current dataset as it requires PET data for each ligand from each participant, but it would be 
interesting to test whether the high-resolution template is fully capable of estimating the 
subject-specific functional response, or if the subject-specific receptor density map would 
provide additional information. This may be of particular importance in long-term MDMA users 
who may have an altered distribution of receptor densities, with a recent meta-analysis 
supporting widespread reductions in 5-HTT density (Muller et al., 2019).  
Ongoing work is also validating this approach with other compounds (i.e. antipsychotics, 
psilocybin). However, high-resolution templates representing the density profiles of other 
receptors such as dopamine will be needed in order to standardise the analysis and test other 
compounds with different affinities. 
 
5. CONCLUSION 
Supported by the receptor occupancy theory, which states that the magnitude of the drug 
response is a function of receptor availability and drug binding, the multimodal approach 
proposed in this study has proven that there is a link between the haemodynamic response to 
MDMA and the underlying neuroreceptor distribution and showed that it is possible to utilise 
receptor maps to enrich connectivity analyses of drug effects. Assuming that drugs modulate 
the neuronal activity in brain regions that have a preferred neurotransmitter affinity (e.g. 
higher receptor density) for them, this new approach defines the drug-specific topography of 
brain functional connectivity and may provide an interesting new fingerprint in the 
characterisation of novel compounds and potentially greater insight to the commonly 
observed eclectic response to treatment. 
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